AAAAAA
Results: 1-25/42
Authors:
TSAVARIS N
TENTAS K
TZIVRAS M
KOSMAS C
KALACHANIS N
KATSIKAS M
DIMITRAKOPOULOS A
PAPASTRATIS G
MACHERAS A
KARATZAS G
SECHAS M
Citation: N. Tsavaris et al., COMBINED EPIRUBICIN, 5-FLUOROURACIL AND FOLINIC ACID VS NO TREATMENT FOR PATIENTS WITH ADVANCED PANCREATIC-CANCER - A PROSPECTIVE COMPARATIVE-STUDY, Journal of chemotherapy, 10(4), 1998, pp. 331-337
Authors:
TSAVARIS N
MYLONAKIS N
BACOYIANNIS C
KOSMAS C
KALERGIS G
IAKOVIDIS V
TZANINIS D
KOSMIDIS P
Citation: N. Tsavaris et al., FACTORS THAT INFLUENCE THE ANTIEMETIC ACTIVITY OF METOCLOPRAMIDE TO CISPLATIN-BASED CHEMOTHERAPY, Oncology Reports, 5(5), 1998, pp. 1147-1155
Authors:
TSAVARIS N
BAXEVANIS CN
KOSMAS C
PAPALAMBROS E
PAPAMICHAEL M
Citation: N. Tsavaris et al., IMMUNE CHANGES IN PATIENTS (PTS) WITH COLON-CANCER (CC) TREATED WITH ADJUVANT THERAPY WITH 17-1A MONOCLONAL-ANTIBODY (MOAB), Annals of oncology, 9, 1998, pp. 204-204
Authors:
ANDROULAKIS N
KOUROUSIS C
DIMOPOULOS AM
SAMELIS G
TSAVARIS N
GENATAS K
PANAGOS G
ARAVANTINOS G
STATHOPOULOS G
GEORGOULIAS V
Citation: N. Androulakis et al., TREATMENT OF PANCREATIC-CANCER WITH DOCETAXEL AND GRANULOCYTE-COLONY-STIMULATING FACTOR - A MULTICENTER PHASE-II STUDY, Annals of oncology, 9, 1998, pp. 255-255
Authors:
POLYZOS A
TSAVARIS N
KOSMAS C
ARNAOUTIS T
APOSTOLOPOULOS P
VAFIADIS I
TSATALI K
TOSKAS A
NIKOU G
Citation: A. Polyzos et al., GEMCITABINE(GEM) PLUS B-FLUOROURACIL (5-FU) BY MODULATED BY LEUCOVORIN (LV) FOR ADVANCED PANCREATIC-CANCER), Annals of oncology, 9, 1998, pp. 262-262
Authors:
KOSMAS C
TSAVARIS N
POLYZOS A
SEPSAS E
MALAMOS N
KALOFONOS HP
PANOPOULOS C
ANTONOPOULOS MJ
Citation: C. Kosmas et al., PACLITAXEL (TAXOL)-IFOSFAMIDE-CISPLATIN (TIP) CHEMOTHERAPY (CMT) REGIMEN IN PATIENTS (PTS) WITH ADVANCED NONSMALL CELL LUNG-CANCER (NSCLC) - A PHASE-II STUDY, Annals of oncology, 9, 1998, pp. 449-449
Authors:
TSAVARIS N
FOUNTZILAS G
MYLONAKIS N
ATHANASSIADIS A
KOSMAS C
KARAKOUSIS C
BACOYIANNIS C
KOSMIDIS P
Citation: N. Tsavaris et al., A RANDOMIZED COMPARATIVE-STUDY OF ANTIEMETIC PROPHYLAXIS WITH ONDANSENTRON IN A SINGLE 32-MG LOADING DOSE VERSUS 8 MG EVERY 6 H IN PATIENTSUNDERGOING CISPLATIN-BASED CHEMOTHERAPY, Oncology, 55(6), 1998, pp. 513-516
Authors:
BRIASOULIS E
TSAVARIS N
FOUNTZILAS G
ATHANASIADIS A
KOSMIDIS P
BAFALOUKOS D
SAMANTAS E
PAVLIDIS N
Citation: E. Briasoulis et al., COMBINATION REGIMEN WITH CARBOPLATIN, EPIRUBICIN AND ETOPOSIDE IN METASTATIC CARCINOMAS OF UNKNOWN PRIMARY SITE - A HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE-II STUDY, Oncology, 55(5), 1998, pp. 426-430
Authors:
POLYZOS A
TSAVARIS N
VESLEMES M
DARDOUFAS K
DOSIOS T
KOSMAS C
Citation: A. Polyzos et al., CHEMOTHERAPY OF NON-SMALL-CELL LUNG-CANCER - A PROSPECTIVELY RANDOMIZED STUDY OF CISPLATIN-ETOPOSIDE VERSUS CISPLATIN-MITOMYCIN-VINBLASTINE, Journal of chemotherapy, 9(2), 1997, pp. 102-105
Authors:
POLYZOS A
TSAVARIS N
GIANNIKOS L
KALAHANIS N
CHRISTODOULOU K
GIANNAKOPOULOS K
NIKOU G
TOSKAS A
PAPARGYRIOU J
KATSILAMBROS N
Citation: A. Polyzos et al., PACLITAXEL (PX) CARBOPLATIN (CBP) VERSUS CYCLOPHOSPHAMIDE (CTX)-CARBOPLATIN SUPPORTED BY G-CSF AS FIRST LINE CHEMOTHERAPY IN FIGO III-IV OVARIAN-CARCINOMA (OC), European journal of cancer, 33, 1997, pp. 545-545
Authors:
GENNATAS CS
PSYCHOGIOS J
DARDOUFAS C
TSAVARIS N
ATHANASIADIS S
Citation: Cs. Gennatas et al., 4-HYDROXYANDROSTENEDIONE (4-OHA) AS 3RD-LINE ENDOCRINE THERAPY IN POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER, European journal of cancer, 33, 1997, pp. 702-702
Authors:
KOSMAS C
TSAVARIS N
POLYZOS A
Citation: C. Kosmas et al., PHASE I II STUDY OF TAXOL/IFOSFAMIDE/CISPLATIN (TIP) COMBINATION CHEMOTHERAPY (CMT) IN ADVANCED SOLID TUMORS (ST)/, European journal of cancer, 33, 1997, pp. 1140-1140
Authors:
TSAVARIS N
KOSMIDIS P
KOSMAS C
KATSIKAS M
BACOYIANNIS C
MYLONAKIS N
PAPALAMBROS E
KOUFOS C
BASTOUNIS E
SECHAS M
Citation: N. Tsavaris et al., CONTRIBUTION OF CHEMOTHERAPY (CMT) TO THE SURVIVAL(S) OF PATIENTS(P) WITH ADVANCED GASTRIC-CANCER (AGC) - A RETROSPECTIVE COMPARATIVE-STUDYOF PATIENTS WHO RECEIVED AND THOSE WHO REFUSED TREATMENT (TX), European journal of cancer, 33, 1997, pp. 1276-1276
Authors:
KOSMIDIS PA
BACOYIANNIS C
FOUNTZILAS G
ARAVANTINOS G
TSAVARIS N
MILATHIANAKIS C
SKARLOS D
Citation: Pa. Kosmidis et al., 5-FLUOROURACIL, INTERFERON-ALPHA-2B AND CISPLATIN (FAP) FOR ADVANCED UROTHELIAL CANCER - A PHASE-II STUDY, Annals of oncology, 8(4), 1997, pp. 373-378
Authors:
ATHANASSIOU A
VARTHALITIS J
TSAVARIS N
DIMITRIDIS M
MOUTZOURIDIS G
Citation: A. Athanassiou et al., SUPERIORITY OF CARBOPLATIN MONOCHEMOTHERAPY OVER CARBOPLATIN-BASED POLYCHEMOTHERAPY IN OVARIAN-CANCER, European journal of gynaecological oncology, 18(5), 1997, pp. 420-425
Authors:
TSAVARIS N
POLYZOS A
KOSMAS C
GIANNIKOS L
GOGAS J
Citation: N. Tsavaris et al., A FEASIBILITY STUDY OF 1-H PACLITAXEL INFUSION IN PATIENTS WITH SOLIDTUMORS, Cancer chemotherapy and pharmacology, 40(4), 1997, pp. 353-357
Authors:
TSAVARIS N
PRIMIKIRIOS N
MYLONAKIS N
VAROUCHAKIS G
DOSIOS T
PAVLIDIS N
SKARLOS D
TASOPOULOS T
DRITSAS J
KOSMIDIS P
Citation: N. Tsavaris et al., COMBINATION CHEMOTHERAPY WITH CISPLATIN AND OR DOXORUBICIN IN MALIGNANT MESOTHELIOMA - A PROSPECTIVE-STUDY/, Anticancer research, 17(5B), 1997, pp. 3799-3802
Authors:
KOSMIDIS PA
TSAVARIS N
SKARLOS D
THEOCHARIS D
SAMANTAS E
PAVLIDIS N
BRIASSOULIS E
FOUNTZILAS G
Citation: Pa. Kosmidis et al., FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT INTERFERON ALFA-2B IN ADVANCED COLORECTAL-CANCER - ANALYSIS OF A PROSPECTIVE RANDOMIZED PHASE-III TRIAL, Journal of clinical oncology, 14(10), 1996, pp. 2682-2687
Authors:
POLYZOS A
TSAVARIS N
GIANNOPOULOS A
BACOYIANNIS C
PAPADIMAS V
KALAHANIS N
KARATZAS G
KOSMAS C
SAKELAROPOULOS N
ARCHIMANDRITIS A
PAPACHRISTODOULOU A
KOSMIDIS P
Citation: A. Polyzos et al., BIOCHEMICAL MODULATION OF FLUOROURACIL - COMPARISON OF METHOTREXATE, FOLINIC ACID, AND FLUOROURACIL VERSUS FOLINIC ACID AND FLUOROURACIL INADVANCED COLORECTAL-CANCER - A RANDOMIZED TRIAL, Cancer chemotherapy and pharmacology, 38(3), 1996, pp. 292-297
Authors:
TSAVARIS N
BAXEVANIS C
KOSMIDIS P
PAPAMICHAEL M
Citation: N. Tsavaris et al., THE PROGNOSTIC-SIGNIFICANCE OF IMMUNE CHANGES IN PATIENTS WITH RENAL-CANCER, MELANOMA AND COLORECTAL-CANCER, TREATED WITH INTERFERON-ALPHA-2B, Cancer immunology and immunotherapy, 43(2), 1996, pp. 94-102
Authors:
BAFALOUKOS D
PAVLIDIS N
FOUNTZILAS G
SKARLOS D
KLOUVAS G
MAKRANTONAKIS P
GIANNAKAKIS T
TSAVARIS N
KOSMIDIS P
Citation: D. Bafaloukos et al., RECOMBINANT INTERFERON ALFA-2A IN COMBINATION WITH CARBOPLATIN, VINBLASTINE, AND BLEOMYCIN IN THE TREATMENT OF ADVANCED MALIGNANT-MELANOMA, American journal of clinical oncology, 19(3), 1996, pp. 296-300
Authors:
KOSMOPOULOU O
FOUKANELI T
TSAVARIS N
AGAPITOS E
SERETIS A
KORDOSSIS T
Citation: O. Kosmopoulou et al., LUNG SQUAMOUS-CELL CARCINOMA PRESENTING WITH BRAIN METASTASES IN AN HIV-POSITIVE PATIENT, Lung cancer, 15(2), 1996, pp. 245-249
Authors:
PATERAKIS GS
TSAVARIS N
LOUKOPOULOS D
Citation: Gs. Paterakis et al., THE EFFECT OF GM-CSF ON RETICULOCYTES, HEMOGLOBIN AND HEMATOCRIT IN PATIENTS RECEIVING CHEMOTHERAPY FOR SOLID TUMORS, Clinical and laboratory haematology, 18(1), 1996, pp. 7-12
Authors:
FOUNTZILAS G
KATSOHIS K
TOUSSIS D
KOSMIDIS P
SEMOGLOU C
FAHANTIDIS E
TSAVARIS N
MAKRANTONAKIS P
ZAMBOGLOU N
HAINOGLOU D
PAVLIDIS N
POLICHRONIS A
GENNATAS K
SKARLOS D
VASSILAROS S
GIANNAKAKIS T
KLOUVAS G
KONSTANTARAS C
KOLOTAS C
TSILIAKOS S
MYLONAKIS N
Citation: G. Fountzilas et al., CYCLOPHOSPHAMIDE, MITOXANTRONE, FLUOROURACIL VERSUS CONVENTIONAL CMF AS ADJUVANT TREATMENT IN NODE-POSITIVE BREAST-CANCER PATIENTS - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY, Oncology, 53(2), 1996, pp. 137-146
Authors:
TSAVARIS N
TENTAS K
KOSMIDIS P
MYLONAKIS N
SAKELAROPOULOS N
KOSMAS C
LISAIOS B
SOUMILAS A
MANDREKAS D
TSETIS A
KLONARIS C
Citation: N. Tsavaris et al., A RANDOMIZED TRIAL COMPARING ADJUVANT FLUOROURACIL, EPIRUBICIN, AND MITOMYCIN WITH NO TREATMENT IN OPERABLE GASTRIC-CANCER, Chemotherapy, 42(3), 1996, pp. 220-226